Tessa Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of cancer immunotherapies. Our goal is to bring hope to cancer patients with no viable treatment options. Today, we are a leader in Virus-Specific T Cell therapy and are conducting the world’s first FDA Phase III T Cell therapy trial in a solid tumor indication.
We will cure cancers and save lives with our innovative and widely accessible immunotherapies.
Science & Technology
The immuno-suppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T Cell (VST) technology overcomes this barrier and has shown early clinical success in treating solid tumors.
We are extending our VST platform to treat a range of solid tumors through combinatorial approaches with Chimeric Antigen Receptors, Antibodies, and Oncolytic Virus technologies.